Evidence for increased filling pressures can be obtained from noninvasive (eg, natriuretic peptide, diastolic function on imaging) or invasive testing (eg, hemodynamic measurement). Value statements were created for select recommendations where high-quality, cost-effectiveness studies of the intervention have been published.Īmyloid heart disease has new recommendations for treatment including screening for serum and urine monoclonal light chains, bone scintigraphy, genetic sequencing, tetramer stabilizer therapy, and anticoagulation.Įvidence supporting increased filling pressures is important for the diagnosis of HF if the LVEF is >40%. These patients should continue their HFrEF treatment. Improved LVEF is used to refer to those patients with previous HFrEF who now have an LVEF >40%. Several prior recommendations have been renewed including treatment of hypertension (Class of Recommendation 1), treatment of atrial fibrillation (Class of Recommendation 2a), use of ARBs (Class of Recommendation 2b), and avoidance of routine use of nitrates or phosphodiesterase-5 inhibitors (Class of Recommendation 3: No Benefit). New recommendations for HFpEF are made for SGLT2i (Class of Recommendation 2a), MRAs (Class of Recommendation 2b), and ARNi (Class of Recommendation 2b).
Weaker recommendations (Class of Recommendation 2b) are made for ARNi, ACEi, ARB, MRA, and beta blockers in this population. SGLT2i have a Class of Recommendation 2a in HF with mildly reduced ejection fraction (HFmrEF). Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) now includes 4 medication classes that include sodium-glucose cotransporter-2 inhibitors (SGLT2i). Suggested Thresholds for Structural Heart Disease and Evidence of Increased Filling Pressures.e1032 Reviewer Relationships With Industry and Other Entities (Comprehensive).e1029Īppendix for Tables 3 and 4. Recommendation for Patient-Reported Outcomes and Evidence Gaps and Future Research Directions e986Įvidence Gaps and Future Research Directions.e986Īuthor Relationships With Industry and Other Entities (Relevant).e1026 Palliative and Supportive Care, Shared Decision-Making, and End-of-Life.e980 Management of Comorbidities in Patients With HF.e969ĭisparities and Vulnerable Populations.e973 Integration of Care: Transitions and Team-Based Approaches.e967 VTE Prophylaxis in Hospitalized Patients.e965Įvaluation and Management of Cardiogenic Shock.e965 Parenteral Vasodilation Therapy in Patients Hospitalized With HF.e964 Maintenance or Optimization of GDMT During Hospitalization.e962ĭiuretics in Hospitalized Patients: Decongestion Strategy.e963 Patients Hospitalized With Acute Decompensated HF.e960Īssessment of Patients Hospitalized With Decompensated HF.e960 Nonpharmacological Management: Advanced HF.e956 HF With Mildly Reduced Ejection Fraction.e948 Heart Failure With Mildly Reduced EF (HFmrEF) and Improved EF (HFimpHF).e948 Other Implantable Electrical Interventions.e945 Pharmacological Treatment for Stage C HFrEF: Soluble Guanylyl Cyclase Stimulators.e941ĭevice and Interventional Therapies for HFrEF.e941 Pharmacological Treatment for Stage C HFrEF (Digoxin).e940 Management of Stage C HF: Ivabradine.e939 GDMT Dosing: Sequencing and Uptitration.e937 Hydralazine and Isosorbide Dinitrate.e933ĭrugs of Unproven Value or That May Worsen HF.e935 Sodium-Glucose Cotransporter 2 Inhibitors.e932 Mineralocorticoid Receptor Antagonists (MRAs).e931 Renin-Angiotensin System Inhibition With ACEi or ARB or ARNi.e928 Management of Stage C HF: Activity, Exercise Prescription, and Cardiac Rehabilitation.e926ĭiuretics and Decongestion Strategies in Patients With HF.e927 Management of Stage B: Preventing the Syndrome of Clinical HF in Patients With Pre-HF.e921 Patients at Risk for HF (Stage A: Primary Prevention).e919
#PARAGON RECOVERY MEDIA BUILDER OPERATION FAILED ERROR 63 SERIAL#
Initial and Serial Evaluation: Clinical Assessment: HF Risk Scoring.e918 Wearables and Remote Monitoring (Including Telemonitoring and Device Monitoring).e916Įxercise and Functional Capacity Testing.e917 Use of Biomarkers for Prevention, Initial Diagnosis, and Risk Stratification.e911 Initial Laboratory and Electrocardiographic Testing.e910 Organization of the Writing Committee.e899Ĭlass of Recommendation and Level of Evidence.e900Ĭlassification of HF by Left Ventricular Ejection Fraction (LVEF).e901ĭiagnostic Algorithm for Classification of HF According to LVEF.e905Ĭlinical Assessment: History and Physical Examination.e908 , MD, PhD, FACC, FAHA, FHFSA, Vice Chair, Customer Service and Ordering InformationĢ022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.
Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).